Please login to the form below
Flixabi
This page shows the latest Flixabi news and features for those working in and with pharma, biotech and healthcare.
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture
Meanwhile, as a rider to the licensing deal, Biogen has also taken on exclusive commercial rights to three other Samsung Bioepis TNF inhibitor biosimilars in China – Benepali (etanercept), Flixabi (infliximab) and
Latest news
-
First Humira biosimilars reach EU market
Samsung Bioepis already has two other biosimilar TNF inhibitors available in Europe - Benepali (etanercept) and Flixabi (infliximab) – giving it an opportunity to quickly leverage its established sales channels in rolling out
-
MSD launches EU’s first biosimilar Herceptin in UK
Ontruzant was the fourth biosimilar developed by the Korean company to receive marketing authorisation in the EU, after Benepali (etanercept), Flixabi (infliximab), and Imraldi (adalimumab).
-
First Herceptin biosimilar cleared in Europe
It has also been granted approval for Benepali (etanercept), Flixabi (infliximab), and Imraldi (adalimumab).
-
New EU and US approvals for Humira biosimilars
TNF blocker after Benepali (etanercept) and Flixabi (infliximab).
-
Biosimilars eat into J&J's Remicade sales
competition from Pfizer's Inflectra, Mundipharma's Remsima and Samsung Bioepis' Renflexis/Flixabi.
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
